Rheumatoid arthritis complicated with severe liver injury during treatment with abatacept

Modern Rheumatology

Volumn 24, Issue 5, 2014, Pages 874-876

  Iwanaga, Nozomi ^a   Origuchi, Tomoki ^b,c   Terada, Kaoru ^a   Ueki, Yukitaka ^a   Kamo, Yasuhiro ^a   Kinoshita, Noboru ^a   Yonemitsu, Nobuhisa ^a   Kawashiri, Shin Ya ^b   Ichinose, Kunihiro ^b   Tamai, Mami ^b   Nakamura, Hideki ^b   Kawakami, Atsushi ^b  

^a SASEBO CHUO HOSPITAL   (Japan)

^b Department of Rheumatology ^*  (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLOOD GROUP A ANTIGEN; BLOOD GROUP B ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; ETANERCEPT; INFLIXIMAB; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; RHEUMATOID FACTOR; TACROLIMUS; TOCILIZUMAB; VIRUS CAPSID ANTIGEN; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CASE REPORT; CHINESE HERB; CONTINUOUS INFUSION; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LIVER BIOPSY; LIVER INJURY; LIVER TRANSPLANTATION; LOSS OF APPETITE; LYMPHOCYTIC INFILTRATION; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIMPLIFIED DISEASE ACTIVITY INDEX; SJOEGREN SYNDROME; THROMBOCYTOPENIA; ARTHRITIS, RHEUMATOID; COMPLICATION; LIVER DISEASE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOCONJUGATES; LIVER DISEASES; MIDDLE AGED;

EID: 84906318519     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.844399     Document Type: Letter

References (22)

1. Chung SJ, Kim JK, Park, MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-Tumor necrosis factor-Alpha therapy. J Rheumatol. 2009;36(11):2416-20.
2. Lan J.L, Chen Y.M, Hsieh T.Y, Chen Y.H, Hsieh C.W, Chen D.Y, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-Tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011; 7 0(10): 1719-25.
3. Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-γ inhibitors. Hepatol Res. 2012; 42(4): 333-9.
4. Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: Safety and clinical management. Expert Opin Biol Ther. 2012;12(2):193-207.
5. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-Tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31(1):118-21.
6. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907-15.
7. Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, et al. Immunogenicity, safety and Efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: Results from accompany, aphase III study. Arthritis Care Res (Hoboken) 2013;65(5):718-28.
8. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infl iximab or abatacept: Open-label extension of the ATTEST Study. Ann Rheum Dis. 2011;70(11):2003-7.
9. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-Term safety, Efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011; 70(10): 1826-30.
10. Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S, et al. Japan Abatacept Study Group. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. 2013;23(2):226-35.
11. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse eff ects of biologics: A network metaanalysis and Cochrane overview. Cochrane Database Syst Rev. 2011; doi: 10.1002/14651858.
12. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classifi cation criteria for Sjögren ' s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-8.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
14. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profi le of infl iximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189-94.
15. HUMIRA Information Network, http://db.e-humira.jp/dra/report/ download.php/224/%E9%81%A9%E6%AD%A3%E4%BD%BF%E7 %94%A8%E6%83%85%E5%A0%B1%20Vol. 5.pdf#search%E3%83%92%E3%83%A5%E3%83%9F%E3%83%A9-%E8%82%9D%E 9%9A%9C%E5%AE%B3 - 3084 '.
16. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and eff ectiveness of etanercept in Japanese patients with rheumatoid arthritis. M. Mod Rheumatol. 2011;21(4):343-51.
17. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients. Ann Rheum Dis. 2011;70(12):2148-51.
18. Sokolove J, Strand V, Greenberg J.D, Curtis J.R, Kavanaugh A, Kremer JM, et al.; CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010; 69(9): 1612-7.
19. Mahamid M, Paz K, Reuven M, Safadi R. Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: Two case reports. Int J Gen Med. 2011;4:657-60.
20. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: A double-edged sword?. Autoimmun Rev. 2010;9(3):188-93.
21. Efe C, Purnak T, Ozaslan E, Wahlin S. Drug-induced autoimmune hepatitis caused by anti-Tumor necrosis factor γ agents. Hepatology. 2010;52(6):2246-7.
22. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Candcado EL. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol, 1999;31(5):929-38.